The estimated Net Worth of Real Estate Equities, Inc.A... is at least $29.6 Milión dollars as of 2 November 2023. Real A owns over 247,258 units of Applied Therapeutics stock worth over $29,072,201 and over the last 4 years Real sold APLT stock worth over $571,166.
Sign up
Real A APLT stock SEC Form 4 insiders trading
Real has made over 2 trades of the Applied Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Real sold 247,258 units of APLT stock worth $571,166 on 2 November 2023.
The largest trade Real's ever made was selling 247,258 units of Applied Therapeutics stock on 2 November 2023 worth over $571,166. On average, Real trades about 96,912 units every 329 days since 2021. As of 2 November 2023 Real still owns at least 5,580,077 units of Applied Therapeutics stock.
You can see the complete history of Real A stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Applied Therapeutics
Over the last 5 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus a Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
What does Applied Therapeutics do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does Applied Therapeutics's logo look like?
Complete history of Real A stock trades at Applied Therapeutics
Applied Therapeutics executives and stock owners
Applied Therapeutics executives and other stock owners filed with the SEC include:
-
shoshana Shendelman,
Chairman of the Board, President, Chief Executive Officer, Founder -
Riccardo Perfetti,
Chief Medical Officer -
Mark Vignola,
Chief Financial Officer -
Dr. Shoshana Shendelman Ph.D.,
Chair of the Board of Directors, Founder, Pres, CEO & Sec. -
Dr. Riccardo Perfetti,
Chief Medical Officer -
Leslie Funtleyder,
Independent Director -
Dr. Charles Silberstein M.D., CFA,
CFO & Head of Bus. Devel. -
Teena Lerner,
Lead Independent Director -
Joel Marcus,
Independent Director -
Stacy Kanter,
Independent Director -
Jay Skyler,
Independent Director -
Maeve Conneighton,
IR Contact Officer -
Adam Hansard,
Chief Commercial Officer -
Chids Mahadevan,
VP of Fin. & Chief Accounting Officer -
Real Estate Equities, Inc.A...,
-
Constantine Chinoporos,
See Remarks -
Charles Silberstein,
Chief Financial Officer -
Adam Hansard,
Chief Commercial Officer -
Corwin Dale Hooks,
Chief Commercial Officer -
Steven A. Ortega,
Principal Accounting Officer -
Chids Mahadevan,
See Remarks